The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2024.
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million.
The report profiles 25 companies including many key and niche players such as:
F. Hoffmann-La Roche Ltd. (Switzerland) GlaxoSmithKline PLC (UK) Eisai Co. Ltd. (Japan) Novo Nordisk A/S (Denmark) Rhythm Pharmaceuticals (USA) VIVUS Inc. (USA) Key Topics Covered
1. Introduction, Methodology & Product Definitions
2. Industry Overview
3. Growth Drivers and Market Trends
Alarming Rise in Global Obesity Levels - The Major Growth Factor Classification of BMI Exponential Increase in Urban Population Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion Growing Middle Class Population to Drive the Market Growth Childhood Obesity - A Market with Unmet Needs Commercial Weight-Loss Companies Foray into the Market Online Drug Stores Boost Sales Barriers to Development of Effective Drugs Regulatory Additions - A Barrier to Entry? High Drug Development Costs - A Major Setback Weight Loss Alternatives - A Market Dampener 4. Select Research Initiatives
5. Obesity - An Introduction
6. Anti-Obesity Drugs - An Insight
7. Competitive Landscape
7.1 Focus on Select Global Players
7.2 Recent Industry Activity
8. Global Market Perspective
Total Companies Profiled: 25 The United States (9)
Japan (2) Europe (8) Germany (1) The United Kingdom (1) Italy (1) Rest of Europe (5) Asia-Pacific (Excluding Japan) (6) For more information about this report visit https://www.researchandmarkets.com/research/7pmxl6/antiobesity?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180817005110/en